{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:49:12Z","timestamp":1771649352002,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00280-020-04226-6","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T10:37:23Z","timestamp":1610534243000},"page":"533-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study"],"prefix":"10.1007","volume":"87","clinical-trial-number":[{"clinical-trial-number":"nct03455907","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Enora","family":"Vaul\u00e9on","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Behal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efc","family":"Lebellec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renaud","family":"Desbarbieux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Pannier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Vieillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2282-0101","authenticated-orcid":false,"given":"Anthony","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"4226_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298\u2013307. https:\/\/doi.org\/10.1038\/nature10144","journal-title":"Nature"},{"key":"4226_CR2","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342. https:\/\/doi.org\/10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"key":"4226_CR3","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542\u20132550. https:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"key":"4226_CR4","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1103799","journal-title":"N Engl J Med"},{"key":"4226_CR5","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473\u20132483. https:\/\/doi.org\/10.1056\/NEJMoa1104390","journal-title":"N Engl J Med"},{"key":"4226_CR6","doi-asserted-by":"publisher","first-page":"208606","DOI":"10.1155\/2012\/208606","volume":"2012","author":"D Graceffa","year":"2012","unstructured":"Graceffa D, Maiani E, Pace A, Solivetti FM, Elia F, De Mutiis C et al (2012) Psoriatic arthritis during treatment with bevacizumab for anaplastic oligodendroglioma. Case Rep Rheumatol 2012:208606. https:\/\/doi.org\/10.1155\/2012\/208606","journal-title":"Case Rep Rheumatol"},{"key":"4226_CR7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1525-1438.2007.01023.x","volume":"18","author":"A Jaishuen","year":"2008","unstructured":"Jaishuen A, Berrios-Rivera JP, Sirisabya N, Zheng HG, Li Y, Kavanagh JJ (2008) Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary. Int J Gynecol Cancer 18:379\u2013383. https:\/\/doi.org\/10.1111\/j.1525-1438.2007.01023.x","journal-title":"Int J Gynecol Cancer"},{"key":"4226_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.4103\/0019-5154.143574","volume":"59","author":"A Datta-Mitra","year":"2014","unstructured":"Datta-Mitra A, Riar NK, Raychaudhuri SP (2014) Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol 59:632. https:\/\/doi.org\/10.4103\/0019-5154.143574","journal-title":"Indian J Dermatol"},{"key":"4226_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s13075-014-0427-y","volume":"16","author":"T Nagai","year":"2014","unstructured":"Nagai T, Sato M, Kobayashi M, Yokoyama M, Tani Y, Mochida J (2014) Bevacizumab, an anti-vascular endothelial growth factor antibody, inhibits osteoarthritis. Arthritis Res Ther 16:427. https:\/\/doi.org\/10.1186\/s13075-014-0427-y","journal-title":"Arthritis Res Ther"},{"key":"4226_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10456-011-9208-2","volume":"14","author":"N Thairu","year":"2011","unstructured":"Thairu N, Kiriakidis S, Dawson P, Paleolog E (2011) Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis 14:223\u2013234. https:\/\/doi.org\/10.1007\/s10456-011-9208-2","journal-title":"Angiogenesis"},{"key":"4226_CR11","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/9467","volume":"5","author":"HP Gerber","year":"1999","unstructured":"Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N (1999) VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5:623\u2013628. https:\/\/doi.org\/10.1038\/9467","journal-title":"Nat Med"},{"key":"4226_CR12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/019262339902700115","volume":"27","author":"AM Ryan","year":"1999","unstructured":"Ryan AM, Eppler DB, Hagler KE, Bruner RH, Thomford PJ, Hall RL et al (1999) Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol Pathol 27:78\u201386. https:\/\/doi.org\/10.1177\/019262339902700115","journal-title":"Toxicol Pathol"},{"key":"4226_CR13","unstructured":"U.S. department of health and human services (2017) Common terminology criteria for adverse events (CTCAE) Version 5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 15 January 2018"},{"key":"4226_CR14","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","volume":"185","author":"S Katz","year":"1963","unstructured":"Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW (1963) Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA 185:914\u2013919. https:\/\/doi.org\/10.1001\/jama.1963.03060120024016","journal-title":"JAMA"},{"key":"4226_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","volume":"9","author":"MP Lawton","year":"1969","unstructured":"Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179\u2013186","journal-title":"Gerontologist"},{"key":"4226_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255\u20131259. https:\/\/doi.org\/10.1016\/S0140-6736(00)02799-9","journal-title":"Lancet"},{"key":"4226_CR17","doi-asserted-by":"crossref","unstructured":"Bannwarth B (2010) Crit\u00e8res d\u2019imputabilit\u00e9 des effets ind\u00e9sirables des m\u00e9dicaments. Rev du Rhum 77:173\u2013175. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S187862271000041X. Accessed Apr 2010","DOI":"10.1016\/j.monrhu.2010.02.007"},{"key":"4226_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0749-0690(18)30752-3","volume":"4","author":"TG Benedek","year":"1988","unstructured":"Benedek TG (1988) Neoplastic associations of rheumatic diseases and rheumatic manifestations of cancer. Clin Geriatr Med 4:333\u2013355","journal-title":"Clin Geriatr Med"},{"key":"4226_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4081\/reumatismo.2018.1069","volume":"70","author":"CU Manzini","year":"2018","unstructured":"Manzini CU, Colaci M, Ferri C, Manzini E (2018) Paraneoplastic rheumatic disorders: a narrative review. Reumatismo 70:199\u2013211. https:\/\/doi.org\/10.4081\/reumatismo.2018.1069","journal-title":"Reumatismo"},{"key":"4226_CR20","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s00520-018-4161-x","volume":"26","author":"R Fernandes","year":"2018","unstructured":"Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK et al (2018) Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study. Support Care Cancer 26:3073\u20133081. https:\/\/doi.org\/10.1007\/s00520-018-4161-x","journal-title":"Support Care Cancer"},{"key":"4226_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00520-015-2777-7","volume":"24","author":"IM Bondarenko","year":"2016","unstructured":"Bondarenko IM, Bias P, Buchner A (2016) Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies. Support Care Cancer 24:267\u2013273. https:\/\/doi.org\/10.1007\/s00520-015-2777-7","journal-title":"Support Care Cancer"},{"key":"4226_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2053369118757537","volume":"24","author":"FE Watt","year":"2018","unstructured":"Watt FE (2018) Musculoskeletal pain and menopause. Post Reprod Health 24:34\u201343. https:\/\/doi.org\/10.1177\/2053369118757537","journal-title":"Post Reprod Health"},{"key":"4226_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","volume":"12","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Herrmann SMS, Herrmann J (2018) Vascular toxicities with VEGF inhibitor therapies\u2013focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 12:409\u2013425. https:\/\/doi.org\/10.1016\/j.jash.2018.03.008","journal-title":"J Am Soc Hypertens"},{"key":"4226_CR24","doi-asserted-by":"publisher","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","volume":"6","author":"M Totzeck","year":"2017","unstructured":"Totzeck M, Mincu RI, Rassaf T (2017) Cardiovascular adverse events in patients with cancer treated with bevacizumab: a meta-analysis of more than 20 000 patients. J Am Heart Assoc 6:e006278. https:\/\/doi.org\/10.1161\/JAHA.117.006278","journal-title":"J Am Heart Assoc"},{"key":"4226_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3389\/fphar.2019.00426","volume":"10","author":"S-P Lee","year":"2019","unstructured":"Lee S-P, Hsu H-C, Tai Y-J, Chen Y-L, Chiang Y-C, Chen C-A et al (2019) Bevacizumab dose affects the severity of adverse events in gynecologic malignancies. Front Pharmacol 10:426. https:\/\/doi.org\/10.3389\/fphar.2019.00426","journal-title":"Front Pharmacol"},{"key":"4226_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001540","author":"J Ventriglia","year":"2020","unstructured":"Ventriglia J, Paciolla I, Pisano C, Tambaro R, Cecere SC, Di Napoli M et al (2020) Arthralgia in patients with ovarian cancer treated with bevacizumab and chemotherapy. Int J Gynecol Cancer. https:\/\/doi.org\/10.1136\/ijgc-2020-001540","journal-title":"Int J Gynecol Cancer"},{"key":"4226_CR27","first-page":"339","volume":"26","author":"CK Giannakopoulos","year":"2005","unstructured":"Giannakopoulos CK, Kyriakidou GK, Toufexi GE (2005) Palmar fasciitis and polyarthritis associated with secondary ovarian carcinoma. Case report Eur J Gynaecol Oncol 26:339\u2013341","journal-title":"Case report Eur J Gynaecol Oncol"},{"key":"4226_CR28","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jhsa.2004.04.012","volume":"29","author":"EA Martorell","year":"2004","unstructured":"Martorell EA, Murray PM, Peterson JJ, Menke DM, Calamia KT (2004) Palmar fasciitis and arthritis syndrome associated with metastatic ovarian carcinoma: a report of four cases. J Hand Surg Am 29:654\u2013660. https:\/\/doi.org\/10.1016\/j.jhsa.2004.04.012","journal-title":"J Hand Surg Am"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04226-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04226-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04226-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:09:05Z","timestamp":1628590145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04226-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4226"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04226-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]},"assertion":[{"value":"6 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethics committee at each participating center approved the study and follow-up protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before inclusion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}